• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AskBio Appoints Clinical Ops Executives

    SpectrumX Partners With UK Contract Manufacturer

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    SpectrumX Partners With UK Contract Manufacturer

    Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership

    Almac Invests $65M to Expand North American HQ

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Catalent to Acquire Metrics Contract Services for $475M
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    UPS to Acquire Healthcare Logistics Provider Bomi Group

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    GL Chemtec Partners with Edgewater Capital to Accelerate Growth

    West Pharmaceutical Makes Strategic Investment in Latch Medical

    “3 Key Trends” with James Park

    Captor Therapeutics Selects CDMO for Clinical Trial Materials

    Behind Every Successful eCOA Solution is a Robust Scientific Strategy
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Societal CDMO

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Vector Partners Limited

    Kyongbo Pharmaceutical
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Societal CDMO

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Vector Partners Limited

    Kyongbo Pharmaceutical
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Process Validation in Biologics Development

    Strategies for successful process validation in the wake of faster approval timelines.

    Process Validation in Biologics Development
    Process Validation in Biologics Development
    Table 1: Typical CQAs for a monoclonal antibody
    Process Validation in Biologics Development
    Table 2: Example Study Recommendations and Supporting Analytical Requirements
    Process Validation in Biologics Development
    Figure 1: Filing and Approval – General Timeline for Large Molecule Drug Substance (DS) and Drug Product (DP)
    Related CONTENT
    • Eurofins PSS Insourcing Solutions
    • Mogene
    • Vetio Animal Health
    • 5 ADC Manufacturing Challenges You Need To Know
    • Nitrosamines
    Victor Vinci and Claudia Berdugo-Davis, Catalent Biologics05.07.19
    The journey from an initial idea through to approval is challenging for any new medicine. Once a promising clinical lead has been chosen, the next step is to make GMP-quality material in larger quantities, using processes that are both robust and reproducible. While this can be difficult for a small molecule drug, it can be even more challenging for a biological drug because of the complex nature of the recombinant protein. It is, therefore, essential that the manufacturing process reliably makes batches that meet product specifications, every time.

    Process validation is an important step for potential therapies that have had early success in the clinic and are progressing toward commercial manufacturing. The process validation strategy should be informed by validation guidelines laid down by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). For example, the 2011 FDA validation guideline1 frames the three stages of validation as a continuum. This article will present a template for a repeatable late-phase development approach that leverages prior knowledge to speed timelines and enable the best chance of success.

    At the beginning of Stage 1, when the molecule moves into development, a target product profile (TPP) has been defined that stipulates the attributes of the molecule that will make it an acceptable drug, considering both its safety and its efficacy. During Stage 1, a process is designed and defined that will allow clinical manufacturing of batches that are sufficiently large to supply Phase 1 and Phase 2 trials. This process should be carefully characterized to provide an insight into how the process (parameters and inputs) links to the chemical and physical attributes of the molecule that is being made.

    In Stage 2, the growing knowledge about both process and product are elaborated upon, with the final stages of manufacturing equipment and facility qualification and process performance qualification (PPQ) being carried out. This will show whether the process is sufficiently robust to make the drug molecule consistently, and the data and control strategy will be part of the biological license application (BLA) filing for the drug. This is also the point at which the commercial manufacturing and life-cycle of the product should be considered in detail in preparation for commercial manufacturing, which occurs in Stage 3.

    Regulatory strategy for process validation
    ICH Q82 is a pivotal document, being one of the first to lay out the requirements for Quality by Design (QbD). This is a process which links what is known about the molecule, both in terms of its structure and its activity, creating the TPP, which leads to the definition of the product’s critical quality attributes (CQAs). These are the attributes of the molecule that can be measured and tested and are linked to patient safety and efficacy. It also contains risk assessments that include raw material attributes. This control strategy should cover everything that is added to the biomanufacturing process, including media and other components of the cell culture, materials required for the drug’s purification, and any excipients that are required for the drug product formulation.

    The TPP is used to inform the late-phase design space, and the information and knowledge about the process is considered from the molecule’s standpoint to identify which aspects are critical, and how they might be controlled to ensure compliance and reproducibility. This control strategy, which is a crucial part of the regulatory filing, expresses how product specifications will be controlled, and also forms a part of the product’s life-cycle, offering an opportunity for constant process verification and continual improvement.

    Previous experience with similar molecules can, and should, be used to inform these decisions. Whether the molecule in question is a monoclonal antibody, a fusion protein, or some other form of molecule produced by DNA expression, there is already a wealth of experience in testing and establishing stability. Initial results from in vitro and in vivo studies on the molecule, and early clinical safety and efficacy data, can also be invaluable here. This can all be linked to the product attributes, with a criticality assessment. All this information will inform the thinking about which critical quality attributes need to be controlled, how manufacturing will ensure that there is sufficient control, and how it will be monitored.

    Critical quality attributes
    A CQA is anything that can impact a drug’s safety, efficacy, and quality. ICH Q8 defines it as “a physical chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality.” All identified CQAs are linked to critical process parameters, based on the risk assessment that is carried out, and a final list of CQAs is generated to map the control strategy. A list of typical CQAs for a monoclonal antibody is shown in Table 1.


    Table 1. Typical CQAs for a monoclonal antibody

    If the molecule is not yet well characterized in the clinic or by biochemical and other testing, an additional risk assessment should be carried out to identify any new CQAs and critical process parameters that should be included. Either way, process characterization and design of experiments (DoE) will be applied.

    Determining the CQAs should be one of the first tasks in a process characterization. It is important to remember that not all molecules – even if they are the same type of molecule, such as a monoclonal antibody – will have the same CQAs. It is, therefore, essential to assess all the knowledge that has been gained about the molecule from early development work to ensure all the CQAs have been correctly identified.

    Although it is possible to make some assumptions with regard to typical CQAs, they are very specific for the individual molecule and every CQA should be associated with critical process parameters to characterize the process and generate a control strategy. This control strategy is a regulatory requirement, and its main objective is to demonstrate that there is a process that will achieve the required quality for the product.

    Based on a criticality risk assessment, a testing plan that is based on the criticality of product attributes should be established. Each CQA should have at least one analytical method, batch record instruction or in process control (IPC), and frequency of monitoring associated with it. Analytical control measurements can be made in-process, for release, after stability testing, and as part of the characterization process. Some CQAs will need to be checked at all of these four stages, such as the absence of aggregates. Others will only be required at certain points; Immunoglobulin G (IgG) concentration, for example, will need to be measured in-process and at release, and protein identification via peptide mapping will only be required as part of the characterization process.

    Some critical process parameters are of a higher risk than others, and at the outset of a process, thoughtful consideration must be given to what represents “acceptable risk” and what does not. There are process parameters that might not impact any of the CQAs but may still affect process performance and will need to be evaluated. Scores from the risk assessment will be used to decide exactly which parameters will be evaluated during the process characterization experiment. Since all the experiments will be on a smaller scale than the final process, a scaled-down model for the process characterization work will be required.

    Different types of experiments can be performed during process characterization, including one-factor-at-a-time (OFAT), multi-factor experiments and DoEs. Depending on the objective and knowledge of the process, there are multiple types of DoEs that can be performed and full factorial and fractional factorial are the screening designs that are traditionally used. Definitive screening design is a relatively new approach, which targets screening with some potential to identify optimization opportunities.  Ultimately, a risk matrix is defined for every operation, and many different studies can be included in this matrix. Table 2 shows an example of this type of matrix for a bioreactor and includes both the process parameters and the categorization from the risk analysis, as well as the impact the process parameters have, and the recommended studies to establish the control strategy.


    Table 2. Example Study Recommendations and Supporting Analytical Requirments

    Careful process characterization is important in the successful completion of pivotal manufacturing batches for Phase 3 trials to take place, and PPQ is an important step. The ICH guidelines serve as a high-level guideline,   however, there are many different approaches to the detailed planning of a PPQ master plan and scheduled GMP batches, and companies can build on their experience and be led by regulatory guidelines to enable the development of best practices.

    Figure 1 gives a general timeline for the filing and approval of large molecules, condensing the points down into key outcomes and key deliverables. There are approaches to hasten development that may come with accelerated approvals and encouraging data from proof-of-concept clinical trials. Efforts to both understand the process, improve and validate methods, and beginning process characterization can be done in parallel in preparation for pivotal batches. A key consideration at this point is to avoid major changes if possible, and to begin stability studies as early as possible. Lessons learned from the process characterization, and the full understanding of the molecule and its critical attributes are the surest means of successful approval and lifecycle of the product. The earlier the process is confirmed, the more likely that changes will only be required if unexpected results and outcomes were to occur. Once all this is completed, primary stability drug substance and drug product batches can be made that will be used for the final process formulation and for fill–finish development. Other considerations to be made at this point will be the container, closure, and other aspects such as the requirement for a syringe.


    Figure 1. Filing and Approval - General Timeline for Large Molecule Drug Substance (DS) and Drug Product (DP)

    Batches for stability testing will also be made, and at this point there are considerable time pressures, not least because a minimum of six months’ stability data is usually required for the biologics license application (BLA) filing. Regulatory bodies are looking to ensure the information on the process is all present and acceptable, so the data from the manufacturing batches, allied to the control strategy and the linkage of CQAs, will all be required for final approval. Ultimately, the solution requires a thorough understanding of the risks and what level of risk will be acceptable.

    Conclusion
    Process validation is a critical step of late-phase development in preparation for commercial launch. Navigating this step quickly and successfully requires integrated planning, timely execution and a deep knowledge of the process and molecule. A thorough understanding of both risk and commercial needs of the molecule also need to be taken into consideration during this pivotal time. Ultimately, it is important to maintain a line-of-sight from clinical development to commercial manufacturing with a view to patient impact. CP

    References
    1. https://www.fda.gov/downloads/drugs/guidances/ucm070336.pdf – Guidance for Industry – Process Validation: General Principles and Practices; FDA January 2011
    2. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf
    Related Searches
    • formulation
    • fda
    • Testing
    • equipment
    Suggested For You
    Eurofins PSS Insourcing Solutions Eurofins PSS Insourcing Solutions
    Mogene Mogene
    Vetio Animal Health Vetio Animal Health
    5 ADC Manufacturing Challenges You Need To Know 5 ADC Manufacturing Challenges You Need To Know
    Nitrosamines Nitrosamines
    Micro-Sphere Partners With PTM Consulting Micro-Sphere Partners With PTM Consulting
    ISPE Releases Good Practice Guide: Process Validation ISPE Releases Good Practice Guide: Process Validation
    Pii Receives EIR From FDA Pii Receives EIR From FDA
    3P Enters Mfg. Tie-up With Dutch Biotech Xenikos 3P Enters Mfg. Tie-up With Dutch Biotech Xenikos
    Support Services Support Services
    Catalent Enters Clinical Supply Partnership with Adial Catalent Enters Clinical Supply Partnership with Adial
    Former FDA Senior Executives Join PAREXEL Former FDA Senior Executives Join PAREXEL
    Heritage Pharma Labs Bolsters Portfolio Heritage Pharma Labs Bolsters Portfolio
    FDA & Data Integrity FDA & Data Integrity
    Lonza Supplies Portola’s Second-Gen Andexxa Lonza Supplies Portola’s Second-Gen Andexxa

    Related Buyers Guide Companies

    • Eurofins PSS Insourcing Solutions

      Eurofins PSS Insourcing Solutions

      ...
      Heather DeGrave, Senior Marketing Specialist 01.07.21

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19


    • 5 ADC Manufacturing Challenges You Need To Know

      5 ADC Manufacturing Challenges You Need To Know

      Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.

    • QA/QC
      Nitrosamines

      Nitrosamines

      How to address these unwelcome guests in the pharmaceutical world
      Aloka Srinivasan, Ph.D., Lachman Consultant Services 05.07.19

    Loading, Please Wait..
    Trending
    • Almac Invests $65M To Expand North American HQ
    • Just – Evotec Biologics And Alpine Immune Sciences Expand Partnership
    • West Pharmaceutical Makes Strategic Investment In Latch Medical
    • AskBio Appoints Clinical Ops Executives
    • Catalent To Acquire Metrics Contract Services For $475M
    Breaking News
    • AskBio Appoints Clinical Ops Executives
    • GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    • SpectrumX Partners With UK Contract Manufacturer
    • Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership
    • Almac Invests $65M to Expand North American HQ
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    What are you Reading this Week?
    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Aug. 13
    'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    Abbott Invests €440 in New Irish Facility
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AskBio Appoints Clinical Ops Executives
    SpectrumX Partners With UK Contract Manufacturer
    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arkay Chairman Emeritus Howard Kaneff Has Died
    Nutricosmetics Market to Hit $13.7 Billion by 2030
    Estée Lauder Pledges 100% Electric Fleet of Vehicles by 2030
    Happi

    Latest Breaking News From Happi

    Consumers are Clamoring for Vintage Glam: Spate
    Kayali’s Lovefest Fragrance, Newell’s New Candle and HydraFacial’s Record Financial Results
    Self Care Trumps Home Care Post-Covid
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Printing Ink Primer, Zeller+Gmelin Lead This Week’s News Stories
    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Esko, Constantia Flexibles announce acquisitions and more
    Hybrid Software joins The Flexo Xperience Center
    Flexo Wash LLC and Mike Potter celebrate 20 years
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Essity Switches to Recyclable Packs for Feminine Pads, FTC Sues PPE Maker on False Origin Claims & More
    Focke & Co. to Host Destination: Your Hygiene Hub on August 31
    Exports Dominate Chinese Trade of Tissues, Hygiene Products and Wipes
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Aug. 13
    Dental 3D Printing Market is Expanding 20% Annually
    Study Results Released for Abbott's Concussion Blood Test
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: ALTANA, Universal Display and Emerson Top This Week’s Stories
    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login